Cargando…

Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis

Gold nanobeacons can be used as a powerful tool for cancer theranostics. Here, we proposed a nanomaterial platform based on gold nanobeacons to detect, target and inhibit the expression of a mutant Kras gene in an in vivo murine gastric cancer model. The conjugation of fluorescently-labeled antisens...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Chenchen, Conde, João, Curtin, James, Artzi, Natalie, Tian, Furong, Cui, Daxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507177/
https://www.ncbi.nlm.nih.gov/pubmed/26189409
http://dx.doi.org/10.1038/srep12297
_version_ 1782381774082408448
author Bao, Chenchen
Conde, João
Curtin, James
Artzi, Natalie
Tian, Furong
Cui, Daxiang
author_facet Bao, Chenchen
Conde, João
Curtin, James
Artzi, Natalie
Tian, Furong
Cui, Daxiang
author_sort Bao, Chenchen
collection PubMed
description Gold nanobeacons can be used as a powerful tool for cancer theranostics. Here, we proposed a nanomaterial platform based on gold nanobeacons to detect, target and inhibit the expression of a mutant Kras gene in an in vivo murine gastric cancer model. The conjugation of fluorescently-labeled antisense DNA hairpin oligonucleotides to the surface of gold nanoparticles enables using their localized surface plasmon resonance properties to directly track the delivery to the primary gastric tumor and to lung metastatic sites. The fluorescently labeled nanobeacons reports on the interaction with the target as the fluorescent Cy3 signal is quenched by the gold nanoparticle and only emit light following conjugation to the Kras target owing to reorganization and opening of the nanobeacons, thus increasing the distance between the dye and the quencher. The systemic administration of the anti-Kras nanobeacons resulted in approximately 60% tumor size reduction and a 90% reduction in tumor vascularization. More important, the inhibition of the Kras gene expression in gastric tumors prevents the occurrence of metastasis to lung (80% reduction), increasing mice survival in more than 85%. Our developed platform can be easily adjusted to hybridize with any specific target and provide facile diagnosis and treatment for neoplastic diseases.
format Online
Article
Text
id pubmed-4507177
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45071772015-07-21 Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis Bao, Chenchen Conde, João Curtin, James Artzi, Natalie Tian, Furong Cui, Daxiang Sci Rep Article Gold nanobeacons can be used as a powerful tool for cancer theranostics. Here, we proposed a nanomaterial platform based on gold nanobeacons to detect, target and inhibit the expression of a mutant Kras gene in an in vivo murine gastric cancer model. The conjugation of fluorescently-labeled antisense DNA hairpin oligonucleotides to the surface of gold nanoparticles enables using their localized surface plasmon resonance properties to directly track the delivery to the primary gastric tumor and to lung metastatic sites. The fluorescently labeled nanobeacons reports on the interaction with the target as the fluorescent Cy3 signal is quenched by the gold nanoparticle and only emit light following conjugation to the Kras target owing to reorganization and opening of the nanobeacons, thus increasing the distance between the dye and the quencher. The systemic administration of the anti-Kras nanobeacons resulted in approximately 60% tumor size reduction and a 90% reduction in tumor vascularization. More important, the inhibition of the Kras gene expression in gastric tumors prevents the occurrence of metastasis to lung (80% reduction), increasing mice survival in more than 85%. Our developed platform can be easily adjusted to hybridize with any specific target and provide facile diagnosis and treatment for neoplastic diseases. Nature Publishing Group 2015-07-20 /pmc/articles/PMC4507177/ /pubmed/26189409 http://dx.doi.org/10.1038/srep12297 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Bao, Chenchen
Conde, João
Curtin, James
Artzi, Natalie
Tian, Furong
Cui, Daxiang
Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
title Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
title_full Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
title_fullStr Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
title_full_unstemmed Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
title_short Bioresponsive antisense DNA gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
title_sort bioresponsive antisense dna gold nanobeacons as a hybrid in vivo theranostics platform for the inhibition of cancer cells and metastasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507177/
https://www.ncbi.nlm.nih.gov/pubmed/26189409
http://dx.doi.org/10.1038/srep12297
work_keys_str_mv AT baochenchen bioresponsiveantisensednagoldnanobeaconsasahybridinvivotheranosticsplatformfortheinhibitionofcancercellsandmetastasis
AT condejoao bioresponsiveantisensednagoldnanobeaconsasahybridinvivotheranosticsplatformfortheinhibitionofcancercellsandmetastasis
AT curtinjames bioresponsiveantisensednagoldnanobeaconsasahybridinvivotheranosticsplatformfortheinhibitionofcancercellsandmetastasis
AT artzinatalie bioresponsiveantisensednagoldnanobeaconsasahybridinvivotheranosticsplatformfortheinhibitionofcancercellsandmetastasis
AT tianfurong bioresponsiveantisensednagoldnanobeaconsasahybridinvivotheranosticsplatformfortheinhibitionofcancercellsandmetastasis
AT cuidaxiang bioresponsiveantisensednagoldnanobeaconsasahybridinvivotheranosticsplatformfortheinhibitionofcancercellsandmetastasis